SciBase AB (SciBase) is a privately held pharmaceutical company that is engaged in developing and providing technology for non-invasive identification and monitoring of skin tissue disorders mainly skin cancer. The company is focused on the development and commercialization of electronic biopsy method for the identification of disorders on skin and mucous membranes. Its patented system consists of a handheld probe that is connected to a computer. SciBase is focused on the improvement of this patented depth selective impedance technology and finding new applications by entering into collaborations with various universities and customers. It is also engaged in providing accurate method for the detection and screening of malignant melanoma and skin cancer. Recently, SciBase has received IDE approval from FDA for the pivotal study to create scientific evidence about the methods accuracy. The company is headquartered in Stockholm, Sweden.